Reviewing Novartis AG (NVS) and Aralez Pharmaceuticals (ARLZ)
Novartis AG (NYSE: NVS) and Aralez Pharmaceuticals (NASDAQ:ARLZ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.
Novartis AG pays an annual dividend of $2.30 per share and has a dividend yield of 2.7%. Aralez Pharmaceuticals does not pay a dividend. Novartis AG pays out 83.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Volatility & Risk
Novartis AG has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Aralez Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.
This table compares Novartis AG and Aralez Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Novartis AG and Aralez Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Novartis AG||$49.18 billion||4.08||$14.46 billion||$2.74||31.23|
|Aralez Pharmaceuticals||$87.22 million||1.08||-$55.02 million||($1.64)||-0.86|
Novartis AG has higher revenue and earnings than Aralez Pharmaceuticals. Aralez Pharmaceuticals is trading at a lower price-to-earnings ratio than Novartis AG, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
11.0% of Novartis AG shares are held by institutional investors. Comparatively, 23.9% of Aralez Pharmaceuticals shares are held by institutional investors. 0.0% of Novartis AG shares are held by insiders. Comparatively, 6.7% of Aralez Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Novartis AG and Aralez Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Novartis AG currently has a consensus price target of $84.44, indicating a potential downside of 1.34%. Aralez Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 467.38%. Given Aralez Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Aralez Pharmaceuticals is more favorable than Novartis AG.
Novartis AG beats Aralez Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company’s range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.